Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02537548 · ClinicalTrials.gov registry record · NA
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
A NA study of Lymphadenopathy and Stage I Testicular Seminoma, sponsored by University of Southern California.
- Active
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 14
- Study locations
NCT02537548: Active NA study of Lymphadenopathy and Stage I Testicular Seminoma, sponsored by University of Southern California.
NCT02537548 is a NA study of Lymphadenopathy and Stage I Testicular Seminoma that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 55 participants, below the 70-participant average among 5 other Lymphadenopathy trials with a reported enrollment target (21% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02537548, a NA study of Lymphadenopathy and Stage I Testicular Seminoma, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.
Primary Outcome
Associated 95% confidence intervals will be constructed. Actuarial RFS will be calculated by the Kaplan Meier method. The recurrence location (pelvic, retroperitoneal, distant) will be calculated as a percentage of total recurrences to describe the clinical pattern of disease after relapse.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Retroperitoneal Lymph Node Dissection
Study Locations (14)
California
- Loma Linda University Medical Center - Loma Linda
- USC / Norris Comprehensive Cancer Center - Los Angeles
- University of California, San Francisco - San Francisco
- Stanford University Hospitals & Clinics - Stanford
Colorado
- University of Colorado Hospital - Aurora - Aurora
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indiana University - Indianapolis
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-08-28 |
| Est. Completion | 2027-08-28 |
| Phase | NA |
What the registry record for NCT02537548 still lists
NCT02537548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 70-participant average among 5 other Lymphadenopathy trials with a reported enrollment target (21% lower).
The record links to 3 conditions, with Lymphadenopathy appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02537548 lists 14 locations in 11 states (California, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT02537548 about?
NCT02537548 is a clinical study titled "Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma". This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that remo...
What is the current status of trial NCT02537548?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2015-08-28. Estimated completion is 2027-08-28.
What conditions does trial NCT02537548 study?
This clinical trial studies the following conditions: Lymphadenopathy, Stage I Testicular Seminoma, Stage II Testicular Seminoma.
What interventions are being tested in trial NCT02537548?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Retroperitoneal Lymph Node Dissection (PROCEDURE).
Who is sponsoring clinical trial NCT02537548?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02537548 being conducted?
This trial has 14 study locations across California, Colorado, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphadenopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
COMPLETED · NA
-
The Analysis of the EBUS Scope as a Hybrid Bronchoscope
COMPLETED · NA
-
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
COMPLETED
-
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI